Early increase of chondroitin sulfate glycosaminoglycan in the glomerular basement membrane of rats with diabetic glomerulopathy.
A decrease in anionic change and the loss of heparan sulfate proteoglycan have previously been observed in the glomerular basement membrane (GBM) during diabetic glomerulosclerosis. We studied the chronological changes in the anionic character and the glycosaminoglycan content in the GBM of WBN/ Kob rats with spontaneous diabetes. Two types of cationic probes were used: polyethyleneimine (PEI) and cationic colloidal gold (CCG). Immunogold labeling was performed with anti-monoclonal-heparan-sulfate-glycosaminoglycan (HS-GAG) and anti-chondroitin-sulfate-glycosaminoglycan (CS-GAG) antibodies. The GBM width, the anionic sites and the GAG sites were investigated in diabetic WBN/Kob rats at 2, 10 and 19 months, compared with control rats. Diabetes was confirmed in WBN/Kob rats after 8 months in this study. The GBM width gradually thickened with age. The PEI anionic sites significantly decreased in the lamina rara externa (LRE) at 19 months (vs. 2 and 10 months). The HS-GAG sites also significantly decreased in the LRE at 10 and 19 months (vs. 2 months). However, the CCG anionic sites and the CS-GAG sites significantly increased in the LRE and the lamina densa at 10 months (vs. 2 months) and, after 19 months, returned to the level seen at 2 months. Results indicate that there is an early transient increase in CS-GAG in the GBM while HS-GAG decreases. We noticed a transient increase in the CCG anionic sites at this early stage of diabetic glomerulosclerosis as well. The increase in CS-GAG may provide a marker for early diabetic changes in the GBM.
Karasawa
R
R
Department of Medicine II, Niigata University, School of Medicine, Japan.
Nishi
S
S
Suzuki
Y
Y
Imai
N
N
Arakawa
M
M
D000818:Animals; D000838:Anions / Q000032:analysis; D000911:Antibodies, Monoclonal; D001485:Basement Membrane / Q000737:chemistry / Q000378:metabolism*; D002809:Chondroitin Sulfates / Q000032:analysis / Q000276:immunology / Q000378:metabolism*; D003924:Diabetes Mellitus, Type 2 / Q000378:metabolism; D003928:Diabetic Nephropathies / Q000378:metabolism*; D004195:Disease Models, Animal; D006497:Heparan Sulfate / Q000032:analysis / Q000276:immunology / Q000378:metabolism; D007150:Immunohistochemistry; D007678:Kidney Glomerulus / Q000737:chemistry / Q000378:metabolism* / Q000473:pathology; D008297:Male; D051381:Rats; D017208:Rats, Wistar
D000838:Anions; D000911:Antibodies, Monoclonal; D002809:Chondroitin Sulfates; D006497:Heparan Sulfate; C038142:chondroitin sulfate glycosaminoglycan